<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538733</url>
  </required_header>
  <id_info>
    <org_study_id>0707009285</org_study_id>
    <secondary_id>RV-MM-PI-238</secondary_id>
    <nct_id>NCT00538733</nct_id>
  </id_info>
  <brief_title>Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma</brief_title>
  <acronym>T-BiRD</acronym>
  <official_title>A Phase II Study of Thalidomide (THALOMID®), Clarithromycin (BIAXIN®), Lenalidomide(REVLIMID®), and Dexamethasone (DECADRON®) for Subjects With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives

        1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin
           (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction
           therapy for patients with newly diagnosed multiple myeloma (MM).

        2. Evaluate the efficacy of the addition of thalidomide (Thalomid®) to BiRD combination
           therapy as a therapy to increase the complete response rate for patients with newly
           diagnosed multiple myeloma.

        3. Evaluate the safety of the combination of clarithromycin, lenalidomide, dexamethasone,
           and thalidomide as a therapy for patients with newly diagnosed MM
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II study is a treatment program for patients with newly diagnosed multiple
      myeloma. Up to 25 patients will be enrolled. Patients who sign consent and fulfill all
      eligibility criteria will be enrolled to receive the following treatment plan:

      T-BiRD Therapy:

      Cycles 1-4

        -  Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first
           28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each
           subsequent cycle)

        -  Clarithromycin (500mg twice daily for each 28 day cycle)

        -  Lenalidomide (25 mg daily days 1-21 of every 28 day cycle) and

        -  Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)

        -  Prophylactic medications will be given.

      After completing 4 cycles

        -  Patients who demonstrate progression of disease will be taken off study.

        -  Patients who achieve maximum response (either by achievement of complete remission or
           stable disease plateau) will be transitioned to maintenance therapy.

        -  Patients who achieve VGPR or PR with acceptable toxicity will be given T-BiRD for an
           additional 2 cycles: cycles 5 and 6.

      Upon completion of 6 cycles of T-BiRD,

        -  Patients who achieve maximum response (either by achievement of complete remission or
           stable disease plateau) will be transitioned to maintenance therapy.

        -  Patients without disease progression or maximum response (either by achievement of
           complete remission or stable disease plateau) will receive BiRD therapy

        -  Patients with disease progression will be taken off study.

      BiRD therapy will consist of the following:

        -  Clarithromycin (500mg twice daily for each 28 day cycle)*

        -  Lenalidomide (25mg daily days 1-21 of every 28 day cycle)*

        -  Dexamethasone (40mg on days 1, 8, 15, 22 of each 28 day cycle)*

        -  Prophylactic medications will be continued.

             -  Patients who finished T-BiRD therapy at reduced doses of clarithromycin,
                lenalidomide or dexamethasone will start BiRD therapy at the same doses of
                clarithromycin, lenalidomide and dexamethasone on which they ended T-BiRD therapy.

      Patients who progress on BiRD will reinitiate T-BiRD as follows:

        -  Thalidomide (100mg/daily for days 1-28 for each 28 day cycle)

        -  Clarithromycin (500mg twice daily for each 28 day cycle)*

        -  Lenalidomide (25mg/daily for days 1-21 of each 28 day cycle)*

        -  Dexamethasone (40mg days 1, 8, 15, 22 of each 28 day cycle)*

        -  Prophylactic medications will be continued

        -  Patients who continue to show disease progression after two cycles of T-BiRD will be
           taken off study.

             -  Patients who finished BiRD therapy at reduced doses of clarithromycin, lenalidomide
                or dexamethasone will start T-BiRD therapy at the same doses of clarithromycin,
                lenalidomide and dexamethasone on which they ended BiRD therapy.

      Transition to maintenance therapy:

      Patients who achieve a resolution of monoclonal gammopathy as detected on serum
      immunofixation or achieve a plateau of disease (no change in quantitative M-spike as detected
      on serum immunofixation) for &gt; 2 cycles on either BiRD or T-BiRD therapy will be transitioned
      to maintenance therapy. Maintenance therapy will be comprised of:

        -  Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)*

        -  Lenalidomide 25 mg daily for days 1-21 out of a 28 day cycle. (15mg daily will be given
           days 1 - 21 out of a 28 day cycle to patients with a creatinine clearance of &lt; 40cc /
           minute).*

        -  Prophylactic medications will be continued

             -  Patients who finished induction therapy with BiRD or T-BiRD at reduced doses
                lenalidomide or dexamethasone will start maintenance therapy at the same doses
                lenalidomide and dexamethasone on which they ended induction therapy. For patients
                with a creatinine clearance of &lt; 40cc / minute, the lenalidomide dose will be the
                lower of their last induction therapy dose or 15mg daily on days 1 - 21 out of a 28
                day cycle.

      At the end of every cycle (which may coincide with day 1 of the new cycle), response and
      toxicity will be evaluated. During cycle 1, patients will have lab work done weekly (CBC with
      differential and blood electrolytes) and female of childbearing potential will have their
      pregnancy testing done, see APPENDIX III. All patients will remain on study until disease
      progression or side effects become excessive. Patients who achieve a stable plateau and are
      on maintenance therapy as defined above may be taken off study if eligible to proceed to high
      dose chemotherapy and autologous stem cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2007</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Drug Combination on Multiple Myeloma</measure>
    <time_frame>This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles</time_frame>
    <description>Objective response rate, defined according to the International Myeloma Working Group (IMWG) criteria as greater then or equal to a Partial Response (PR). The best response was recorded. The IMWG criteria can be found here: imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Maximum Response</measure>
    <time_frame>from baseline to cycle with maximum response</time_frame>
    <description>Median Time to maximum response, reported in cycles of treatment. One cycle = 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>from baseline to the time of first event that lead to removal from study (defined as progression, death, withdrawal of consent, or removal for toxicity)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From start of treatment, to the date of first progression</time_frame>
    <description>Progression determined using International Myeloma Working Group criteria, as defined below.
An increase of &gt; 25% from lowest response value one or more of the following:
Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL)*
Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h)
Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be &gt; 10 mg/dL
Bone marrow plasma cell percentage; the absolute percentage must be &gt; 10%
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcaemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder *if starting serum M protein is greater then 5 g/dL, absolute increase of 1g/dL is sufficient to determine relapse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>T-BiRD Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).
After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.
Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.
Patients in CR/sCR or that achieve a plateau of disease for &gt; 2 cycles on BiRD or T-BiRD therapy will receive maintenance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalomid</intervention_name>
    <description>Cycles 1-4
• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)</description>
    <arm_group_label>T-BiRD Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)
• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)
During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)
During Maintenance Phase
• 25 mg daily for days 1-21 out of a 28 day cycle</description>
    <arm_group_label>T-BiRD Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
    <description>During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)
During BiRD Phase:
• Clarithromycin (500mg twice daily for each 28 day cycle)</description>
    <arm_group_label>T-BiRD Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)
• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)
During BiRD Phase:
• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)
During Maintenance Phase
• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)</description>
    <arm_group_label>T-BiRD Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must voluntarily sign and understand written informed consent.

          -  Age &gt; 18 years at the time of signing the consent form.

          -  Histologically confirmed Salmon-Durie stage II or III MM. Stage I MM patients will be
             eligible if they display poor prognostic factors (ß2M ≥5.5 mg/L, plasma cell
             proliferation index ≥5%, albumin of less then 3.0, and unfavorable cytogenetics).

          -  Newly diagnosed myeloma.

          -  No anti-myeloma therapy within 14 days prior to initiation of study treatment except
             for corticosteroids with a maximum allowed dosage equivalent to three pulses of
             dexamethasone (40mg daily for 4 days equals one pulse). Patients may be receiving
             adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine
             care.

          -  Measurable disease as defined by &gt; 1.0 g/dL serum monoclonal protein, &gt;0.1 g/dL serum
             free light chains, &gt;0.2 g/24 hrs urinary M-protein excretion, and/or measurable
             plasmacytoma(s).

          -  Karnofsky performance status ≥70% (&gt;60% if due to bony involvement of myeloma.

          -  Able to take aspirin daily as prophylactic anticoagulation. (patients intolerant to
             ASA may use warfarin or low molecular weight heparin)

          -  All study participants must be registered into the mandatory RevAssist® and
             S.T.E.P.S.® programs, and be willing and able to comply with the requirements of
             RevAssist® and the S.T.E.P.S.® programs.

          -  Females of childbearing potential (FCBP)† must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of prescribing lenalidomide and thalidomide (prescriptions
             must be filled within 7 days) and must either commit to continued abstinence from
             heterosexual intercourse or begin TWO acceptable methods of birth control, one highly
             effective method and one additional effective method AT THE SAME TIME, at least 4
             weeks before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy
             testing. Men must agree to use a latex condom during sexual contact with females of
             child bearing potential even if they have had a successful vasectomy.

          -  Life expectancy ≥ 3 months

          -  Subjects must meet the following laboratory parameters:

               -  Absolute neutrophil count (ANC) ≥1000 cells/mm3 (1.0 x 109/L)

               -  Platelets count ≥ 75,000/mm3 (75 x 109/L)

               -  Serum SGOT/AST &lt;3.0 x upper limits of normal (ULN)

               -  Serum SGPT/ALT &lt;3.0 x upper limits of normal (ULN)

               -  Serum creatinine &lt;2.5 mg/dL (221 µmol/L)

               -  Serum total bilirubin &lt;2.0 mg/dL (34 µmol/L)

        Exclusion Criteria:

          -  Patients with non-secretory MM (no measurable monoclonal protein, free light chains,
             and/or M-spike in blood or urine).

          -  Prior history of other malignancies (except for basal cell or squamous cell carcinoma
             of the skin or carcinoma in situ of the cervix or breast) unless disease free for ≥ 5
             years.

          -  Myocardial infarction within 6 months prior to enrollment , or NYHA(New York Hospital
             Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities.

          -  Pregnant or lactating females are ineligible.

          -  Given the potential of the study drugs to trigger or worsen HIV viremia and the
             incidence of opportunistic infections inpatients infected with the HIV virus, HIV-1 or
             HIV-2 positive patients will be excluded. The interactions of HAART with study drugs
             have not been determined.

          -  Active hepatitis B or hepatitis C infection.

          -  Active viral or bacterial infections or any coexisting medical problem that would
             significantly increase the risks of this treatment program.

          -  Any coexisting medical problem or laboratory evaluation that, in the treating
             physician's or principal investigator's opinion, makes the patient unsuitable to
             participate in this clinical trial.

          -  Known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide.

          -  History of thromboembolic event within the past 6 months prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Niesvizky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.cornell.edu/cancercare/trials/</url>
    <description>WCMC website</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2007</study_first_posted>
  <results_first_submitted>February 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2017</results_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloma</keyword>
  <keyword>newly diagnosed multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T-BiRD Therapy (All Patients)</title>
          <description>26 patients started the treatment phase. Per protocol, completion of the treatment phase was defined as removal from treatment due to progression, or to pursue an alternative treatment (either a stem cell transplant, or further consolidation chemotherapy in pursuit of a transplant).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Removed Due to Progression of Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Removed to Pursue a Stem Cell Transplant</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Removed to Pursue Alternative Theray</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>declined to participate</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>still on therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T-BiRD Therapy (All Patients)</title>
          <description>All patients that enrolled on the study and received treatment with T-BiRD are included in this analysis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="40" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Durie-Salmon Classification</title>
          <description>The Durie Salmon Staging System was used to assess patients clinical status. Stage 1A is associated with a better outcome and a low tumor burden, stage 2A is associated with a intermediate outcome and tumor burden, and stage 3A is associated with a worse outcome and higher tumor burden. Patients are classified into each stage based on multiple criteria including hemoglobin and calcium values, disease burden, and renal function.
The Durie Salmon Staging System can be found here: https://www.themmrf.org/multiple-myeloma/prognosis/myeloma-stages/durie-salmon-staging-system/</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage 1A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 3A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytogenetics</title>
          <description>Cytogenetic analysis was done on all patients to determine if they were of standard or high risk. Cytogenetics were performed on bone marrow cultures.
Standard risk was defined by the presence of one or more of the following on : t(11;14); hyperdiploidy; del 13q14 detected using florescence in situ hybridization (FISH); no abnormality High risk was defined by the presence of one or more of the following: del 17p; karyotype del 13q; amp 1q/del 1p; t(14;20); t(14;16); t(4;14)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>standard risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunoglobulins</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IgA myeloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG myeloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>light chain only myeloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>karnofsky performance status</title>
          <description>Normal, no complaints = 100%; Able to carry on normal activities. Minor signs or symptoms of disease = 90%; Normal activity with effort = 80%; Care for self. Unable to carry on normal activity or to do active work = 70%; Requires occasional assistance, but able to care for most of his needs= 60% Requires considerable assistance &amp; frequent medical care = 50%; Disabled. Requires special care &amp; assistance = 40%; Severely disabled. Hospitalization indicated though death nonimminent = 30%; Very Sick, hospitalization necessary. Active supportive treatment necessary = 20%; moribund =10%; dead = 0%</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>90% (or better)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Staging System Classification</title>
          <description>Stage I ß2-M &lt; 3.5 mg/dL and albumin =3.5 g/dL
Stage II Neither stage I nor stage III
Stage III ß2-M ≥ 5.5 mg/L</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin at baseline (in g/dL)</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.95" lower_limit="9.1" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>serum creatinine at baseline (in mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.85" lower_limit="0.5" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>platelet count at baseline (in 1000/uL)</title>
          <units>1000/uL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241" lower_limit="87" upper_limit="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>absolute neutrophil count at baseline (in 1000/uL)</title>
          <units>1000/uL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="0.9" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>albumin at baseline (in mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="2.2" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>lactage dehydrogenase at baseline (U/L)</title>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151" lower_limit="92" upper_limit="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein at baseline (in mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.225" lower_limit="0.03" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta-2 microglobulin at baseline (in mg/L)</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" lower_limit="1.2" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Drug Combination on Multiple Myeloma</title>
        <description>Objective response rate, defined according to the International Myeloma Working Group (IMWG) criteria as greater then or equal to a Partial Response (PR). The best response was recorded. The IMWG criteria can be found here: imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/</description>
        <time_frame>This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles</time_frame>
        <population>25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>T-BiRD Therapy (All Patients)</title>
            <description>26 patients started the treatment phase. Per protocol, completion of the treatment phase was defined as removal from treatment due to progression, or to pursue an alternative treatment (either a stem cell transplant, or further consolidation chemotherapy in pursuit of a transplant). 25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Drug Combination on Multiple Myeloma</title>
          <description>Objective response rate, defined according to the International Myeloma Working Group (IMWG) criteria as greater then or equal to a Partial Response (PR). The best response was recorded. The IMWG criteria can be found here: imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/</description>
          <population>25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sCR (stringent complete response)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VGPR (very good partial response)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR (partial response)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD (stable disease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Maximum Response</title>
        <description>Median Time to maximum response, reported in cycles of treatment. One cycle = 28 days.</description>
        <time_frame>from baseline to cycle with maximum response</time_frame>
        <population>25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>T-BiRD Therapy (All Patients)</title>
            <description>25 of the 26 patients enrolled onto the were assessed for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Maximum Response</title>
          <description>Median Time to maximum response, reported in cycles of treatment. One cycle = 28 days.</description>
          <population>25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</population>
          <units>cycles</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Survival</title>
        <time_frame>from baseline to the time of first event that lead to removal from study (defined as progression, death, withdrawal of consent, or removal for toxicity)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-BiRD Therapy (All Patients)</title>
            <description>All 26 patients that were enrolled onto the study were assessed for event free survival.</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="4.2" upper_limit="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression determined using International Myeloma Working Group criteria, as defined below.
An increase of &gt; 25% from lowest response value one or more of the following:
Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL)*
Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h)
Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be &gt; 10 mg/dL
Bone marrow plasma cell percentage; the absolute percentage must be &gt; 10%
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcaemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder *if starting serum M protein is greater then 5 g/dL, absolute increase of 1g/dL is sufficient to determine relapse.</description>
        <time_frame>From start of treatment, to the date of first progression</time_frame>
        <population>25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>T-BiRD Therapy (All Patients)</title>
            <description>25 of the 26 patients enrolled onto the were assessed for progression, as one patient expired prior to first response assessment and could not be included in the analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression determined using International Myeloma Working Group criteria, as defined below.
An increase of &gt; 25% from lowest response value one or more of the following:
Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL)*
Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h)
Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be &gt; 10 mg/dL
Bone marrow plasma cell percentage; the absolute percentage must be &gt; 10%
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcaemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder *if starting serum M protein is greater then 5 g/dL, absolute increase of 1g/dL is sufficient to determine relapse.</description>
          <population>25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" lower_limit="14.1">n/a has been entered because this was not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (serious and non-serious) were recorded from first dose of study drug, until removal from study (treatment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T-BiRD Therapy (All Patients)</title>
          <description>All 26 patients that were enrolled onto the study were assessed for adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness/fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>accompanied by dysgeusia and rash</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>multiple compression fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal insufficiency/Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash (steven johnson syndrome)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>unspecified infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>bacterial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia/dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychomotor agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Hess</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>6469629440</phone>
      <email>jmh2004@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

